+

WO2006112283A1 - Agent anti-fatigue - Google Patents

Agent anti-fatigue Download PDF

Info

Publication number
WO2006112283A1
WO2006112283A1 PCT/JP2006/307529 JP2006307529W WO2006112283A1 WO 2006112283 A1 WO2006112283 A1 WO 2006112283A1 JP 2006307529 W JP2006307529 W JP 2006307529W WO 2006112283 A1 WO2006112283 A1 WO 2006112283A1
Authority
WO
WIPO (PCT)
Prior art keywords
crocetin
fatigue
acid
food
rats
Prior art date
Application number
PCT/JP2006/307529
Other languages
English (en)
Japanese (ja)
Inventor
Takashi Kahara
Naofumi Umigai
Masahiro Takahashi
Katsura Funayama
Original Assignee
Riken Vitamin Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Riken Vitamin Co., Ltd. filed Critical Riken Vitamin Co., Ltd.
Priority to JP2007521188A priority Critical patent/JPWO2006112283A1/ja
Publication of WO2006112283A1 publication Critical patent/WO2006112283A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A23L2/58—Colouring agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
    • A23L5/40—Colouring or decolouring of foods
    • A23L5/42—Addition of dyes or pigments, e.g. in combination with optical brighteners
    • A23L5/43—Addition of dyes or pigments, e.g. in combination with optical brighteners using naturally occurring organic dyes or pigments, their artificial duplicates or their derivatives
    • A23L5/44—Addition of dyes or pigments, e.g. in combination with optical brighteners using naturally occurring organic dyes or pigments, their artificial duplicates or their derivatives using carotenoids or xanthophylls
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to an anti-fatigue agent and a food or drink containing crocetin or a pharmacologically acceptable salt thereof as an active ingredient.
  • Fatigue is defined as a temporary qualitative or quantitative decline in physical and mental work ability that occurs when physical or mental stress is applied continuously. ing. And when it doesn't recover spontaneously and you can't get out of the state of being tired all the time, you get close to a condition called chronic fatigue or actually get sick.
  • vitamin B groups such as 1 2 6 1.
  • vitamin C vitamin C, vitamin E, etc. also have the function of preventing cell oxidization and improving blood flow. Therefore, it has been said that it is important to eat foods rich in these vitamins.
  • a preparation or food containing a compound effective for fatigue recovery for example, a preparation containing L-calcintin L-tartrate (see Patent Document 1), piotin, carcin and pantothenic acid as active ingredients Containing fatigue improving agent (see Patent Document 2), anti-fatigue agent containing idebenone or its hydroquinone as an active ingredient (see Patent Document 3), organic acid having two or more carboxyl groups (taenoic acid) , Malic acid, tartaric acid, fumaric acid, adipic acid and succinic acid) or their salts as active ingredients (see Patent Document 4), L-carcin and histidine-related dipeptides (carnosine) contained in livestock meat , Anserine, valenine) and taurine have been proposed for physical strength enhancement materials for fatigue recovery and foods using the same (see Patent Document 5).
  • Patent Document 1 Japanese Patent Laid-Open No. 4-128223
  • a crocetin-containing composition such as an oil or fat composition mainly composed of crocetin or a pharmacologically acceptable salt thereof, an oZw type emulsion, a wZo type emulsion or a solubilized solution is produced according to a conventional method.
  • the crocetin-containing composition may be added to a food or drink to produce the food or drink of the present invention.
  • the food and drink may take any food form such as a solid food, a cream-like or jam-like semi-solid food, a gel food, and a beverage.
  • Examples of food and drink include soft drinks, drops, candy, chewing gum, chocolate, gummi, yogurt, ice cream, pudding, jelly confectionery, cookies, margarine, shortening, mayonnaise and dressing.
  • the above food and drink are intended for the prevention or recovery of specified health foods with a label indicating that they are used for the prevention or recovery of fatigue, or the accumulation of fatigue and various illnesses that accompany it. Useful as a health food.
  • Crocetin administration group sample Purified crocetin (color value: 34, 200) Weigh accurately 20.00 g, pulverize in an agate mortar, add 0.5 mass% sodium carboxymethylcellulose aqueous solution little by little, and mix accurately. The test solution was 10 mL.
  • rats were divided into groups of 5 animals by random sampling by rank.
  • the day of grouping was defined as dayO, and the sample solution was administered by oral gavage once a day from dayO to day6 at a rate of lmL per lOOg of rat body weight. During this time, the body weight, food intake and water intake of the rats were measured daily.
  • a weight swimming test was performed on dayl2. Put water (water temperature 23 ⁇ 1 ° C) to a height of 40cm in a tank, tie a weight of 8% by weight of the weight to the base of the tail with a string, and forcibly swim the rat. Time was measured.
  • the rats in the crocetin-administered group lost a small amount of body weight. Although a small trend was observed, it did not significantly decrease during the period. On the other hand, weight loss was observed in rats in the control group and the citrate-treated group. As a result of testing the difference in the mean value between the control group and the crocetin-treated group by Dunnet method, the difference was statistically significant on both days (risk rate 5). %)Met. This result shows that the anti-fatigue agent of the present invention is useful for fatigue during insomnia.
  • the rats in the crocetin-administered group (Example) recorded a swimming time of 144.8 ⁇ 37.2 seconds, compared to the rats in the control group (swimming time; 65.6 ⁇ 12.4 seconds). It was statistically significant (risk rate 5%).
  • the rats in the kenic acid group recorded a swimming time of 84.4 ⁇ 14.4 seconds, and the swimming time was prolonged compared with the rats in the control group, but the difference was not statistically significant. I helped.
  • Crocetin or a pharmacologically acceptable salt thereof used in the present invention has an excellent anti-fatigue effect as compared with citrate, which has been reported to be effective for recovery from fatigue in the conventional furrow.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Agent anti-fatigue ou boisson comprenant de la crocétine représentée par la formule ci-dessous ou un sel de celle-ci acceptable sur le plan pharmaceutique comme ingrédient actif. L’agent anti-fatigue et la boisson sont utiles pour la prévention de la fatigue ou la récupération suite à la fatigue. [Formule chimique]
PCT/JP2006/307529 2005-04-13 2006-04-10 Agent anti-fatigue WO2006112283A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2007521188A JPWO2006112283A1 (ja) 2005-04-13 2006-04-10 抗疲労剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005116079 2005-04-13
JP2005-116079 2005-04-13

Publications (1)

Publication Number Publication Date
WO2006112283A1 true WO2006112283A1 (fr) 2006-10-26

Family

ID=37115008

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2006/307529 WO2006112283A1 (fr) 2005-04-13 2006-04-10 Agent anti-fatigue

Country Status (2)

Country Link
JP (1) JPWO2006112283A1 (fr)
WO (1) WO2006112283A1 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007141898A1 (fr) * 2006-06-02 2007-12-13 Riken Vitamin Co., Ltd. Agent améliorant la tension oculaire
JP2008239528A (ja) * 2007-03-26 2008-10-09 Lion Corp 目及び脳機能改善剤
JP2008273939A (ja) * 2007-03-30 2008-11-13 Riken Vitamin Co Ltd 睡眠改善剤
JP2011502539A (ja) * 2007-11-16 2011-01-27 バイオ クリニカル デベロップメント，インコーポレイテッド 低カフェイン可食性活力組成物
JP2014218483A (ja) * 2013-05-10 2014-11-20 ハウス食品グループ本社株式会社 クチナシ抽出物を含む眠気覚まし用組成物
US9049879B2 (en) 2008-06-13 2015-06-09 International Ip Holdings Llc Edible energy composition
JP2015520229A (ja) * 2012-06-22 2015-07-16 ケー−パックス・ファーマシューティカルズ・インコーポレイテッド 神経心理学的障害の治療用の組成物および方法
US9119413B2 (en) 2008-06-13 2015-09-01 International Ip Holdings Llc Edible energy composition
JP2017012059A (ja) * 2015-06-30 2017-01-19 富士フイルム株式会社 食品組成物
US10881661B2 (en) 2008-06-13 2021-01-05 International Ip Holdings Llc Edible energy composition

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3788468A (en) * 1973-05-01 1974-01-29 Univ Virginia Process for increasing oxygen diffusivity
JPH10175856A (ja) * 1996-10-14 1998-06-30 Taisho Pharmaceut Co Ltd 疲労改善剤
US6060511A (en) * 1995-10-05 2000-05-09 Gainer; John L. Trans-sodium crocetinate, methods of making and methods of use thereof
WO2003072734A2 (fr) * 2002-02-25 2003-09-04 Diffusion Pharmaceuticals Llc Sels carotenoides trans bipolaires et leurs utilisations
JP2005225842A (ja) * 2004-02-16 2005-08-25 Riken Vitamin Co Ltd 脳機能改善剤

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3788468A (en) * 1973-05-01 1974-01-29 Univ Virginia Process for increasing oxygen diffusivity
US6060511A (en) * 1995-10-05 2000-05-09 Gainer; John L. Trans-sodium crocetinate, methods of making and methods of use thereof
JPH10175856A (ja) * 1996-10-14 1998-06-30 Taisho Pharmaceut Co Ltd 疲労改善剤
WO2003072734A2 (fr) * 2002-02-25 2003-09-04 Diffusion Pharmaceuticals Llc Sels carotenoides trans bipolaires et leurs utilisations
JP2005225842A (ja) * 2004-02-16 2005-08-25 Riken Vitamin Co Ltd 脳機能改善剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GHOSAL S. ET AL.: "Mangicrocin, an Adaptogenic Xanthone-Carotenoid Glycosidic Conjugate from Saffron", JOURNAL OF CHEMICAL RESEARCH, SYNPOSES, 1989, pages 70 - 71 *

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007141898A1 (fr) * 2006-06-02 2007-12-13 Riken Vitamin Co., Ltd. Agent améliorant la tension oculaire
JP2008239528A (ja) * 2007-03-26 2008-10-09 Lion Corp 目及び脳機能改善剤
JP2008273939A (ja) * 2007-03-30 2008-11-13 Riken Vitamin Co Ltd 睡眠改善剤
US9526268B2 (en) 2007-11-16 2016-12-27 International Ip Holdings Llc Edible energy composition with low caffeine
JP2011502539A (ja) * 2007-11-16 2011-01-27 バイオ クリニカル デベロップメント，インコーポレイテッド 低カフェイン可食性活力組成物
US11540551B2 (en) 2007-11-16 2023-01-03 International Ip Holdings Llc Edible edible composition with low caffeine
US8993033B2 (en) 2007-11-16 2015-03-31 International Ip Holdings, Llc Edible energy composition with low caffeine
US10721955B2 (en) 2007-11-16 2020-07-28 International Ip Holdings Llc Edible energy composition with low caffeine
US10201179B2 (en) 2007-11-16 2019-02-12 International Ip Holdings Llc Edible energy composition with low caffeine
US9616080B2 (en) 2008-06-13 2017-04-11 International Ip Holdings Llc Edible energy composition
US9480697B2 (en) 2008-06-13 2016-11-01 International Ip Holdings Llc Edible energy composition
US9119413B2 (en) 2008-06-13 2015-09-01 International Ip Holdings Llc Edible energy composition
US10471085B2 (en) 2008-06-13 2019-11-12 International Ip Holdings Llc Edible energy composition
US9049879B2 (en) 2008-06-13 2015-06-09 International Ip Holdings Llc Edible energy composition
US10881661B2 (en) 2008-06-13 2021-01-05 International Ip Holdings Llc Edible energy composition
JP2015520229A (ja) * 2012-06-22 2015-07-16 ケー−パックス・ファーマシューティカルズ・インコーポレイテッド 神経心理学的障害の治療用の組成物および方法
JP2014218483A (ja) * 2013-05-10 2014-11-20 ハウス食品グループ本社株式会社 クチナシ抽出物を含む眠気覚まし用組成物
JP2017012059A (ja) * 2015-06-30 2017-01-19 富士フイルム株式会社 食品組成物

Also Published As

Publication number Publication date
JPWO2006112283A1 (ja) 2008-12-11

Similar Documents

Publication Publication Date Title
WO2006112283A1 (fr) Agent anti-fatigue
JP7008909B2 (ja) カンナビジオール又は大麻抽出物とカフェインを含む組成物及びその応用
JP6745250B2 (ja) モリンガエキス
JP6581902B2 (ja) エネルギー消費の促進および／またはエネルギー消費機能低下の治療および／または予防剤、または方法
JP5188181B2 (ja) 血中アルコール濃度上昇抑制用組成物
JPWO2007037438A1 (ja) メタボリックシンドローム改善・予防組成物
WO2008035757A1 (fr) Aliment de type gelée contenant de l'ubiquinol
JP5705898B2 (ja) 肝機能改善剤
KR20140021598A (ko) 조성물, 및 당대사 개선제, 및 당대사 개선방법
TW201828955A (zh) 提高耐力表現之抗疲勞組合物
JPH0920660A (ja) 抗ストレス組成物
JP2003310212A (ja) 水分散性又は水溶解性のバナバ葉抽出物組成物
JPH10265397A (ja) 肥満予防剤
WO1998035664A1 (fr) Agent augmentant l'endurance athletique et aliment le contenant
JP2024100951A (ja) アトロジン－１発現抑制剤
JP5710091B2 (ja) Ｎｏ産生促進剤
JP2013192515A (ja) 牡蠣エキス
JP2020164495A (ja) 男性活力用組成物及び組成物
JP2005213185A (ja) エネルギー補給および抗疲労飲食品
JP2008074734A (ja) インスリン抵抗性改善剤
JP7162917B2 (ja) 心拍数低下剤
JP2010037221A (ja) アディポネクチン産生増強剤
RU2670612C9 (ru) Композиция для предупреждения или лечения ожирения, содержащая α-липоевую кислоту и N-ацетилцистеин в качестве активных ингредиентов
JP5362976B2 (ja) 血流改善剤
JP4523236B2 (ja) 抗ストレス剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2007521188

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06731476

Country of ref document: EP

Kind code of ref document: A1

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载